Emerging biotechs are researching once forbidden drugs to solve some of the most vexing medical problems...those of mental health.
Major investors have launched this sector with over a half-billion dollars in start-up capitalization and they’re already seeing substantial returns!
This trend is just getting started!
Forbes reports that the emerging market in new psychoactive mental health medications... “could bring in a whopping $6.85 billion by 2027.”1
We are Now Entering Phase Two of a Pharmaceutical Renaissance
Research is mounting. An entirely new class of psychoactive medications is showing profound efficacy in treating mental disorders and traumatic brain injuries.
This is cutting edge medical science that has been buried for decades by out-of-date taboos. But times are changing.
Findings are that once-forbidden psycho-active compounds now being extracted from organic sources hold significant promise for treating, even curing mental disorders and injuries once thought to be incurable.
Legal restrictions formerly kept these compounds out of the lab, their benefits remained clouded in secrecy. Now those secrets are coming to light and it appears clear to many that was a HUGE missed opportunity.
The market for psychoactive medicines and drug therapies could accelerate many times faster than what investors anticipated from the cannabis market.
This projected market growth can be expected to drive innovative, start-up biotech companies to rapid growth over the coming months. Some early starters have already achieved significant growth as eager investors rushed to establish ground floor positions.
What’s compelling is that those ground-floor positions have been launched by high-net-worth investors that now fuel the trajectory of this soaring market trend.
WE HAVE SPECIAL ACCESS FOR OUR SUBSCRIBERS TO READ THE FULL REPORT ON THIS GROUND FLOOR OPPORTUNITY